A more cautious stance is warranted, as stocks face intensifying headwinds. Read More

Owning stocks of strong companies that pay dividends in foreign currency can help bolster your portfolio's overall return. Read More

The unfortunate passing of this fund's manager raises questions about whether this fund will be able to maintain its track record of success. Read More

This chemical producer stands to benefit from rising commodity prices as well as a favorable acquisition. Read More

Article in Review: “Advertising Growth,” by Benjamin Shepherd, February 23, 2011 Read More

Promising drug start-ups beckon investors with their siren’s call, but your best bet is to stick with established pharmaceutical firms. Read More

Afflicted by a wave of patent expirations and several high-profile class-action lawsuits, the pharmaceutical industry has suffered its fair share of ailments in recent years. Accordingly, the S&P 500 Pharmaceuticals Index has returned a paltry 16.5 percent over the past half-decade.  In contrast, the New York Stock Exchange ARCA Biotechnology… Read More

Energy price spikes are spooking investors, but you shouldn't overreact. Read More

In 2006 the yield on a 10-year US government bond hovered around 5 percent; corporate bonds rated BBB by Standard & Poor’s yielded between 6.5 and 7 percent. Conservative investors seeking regular monthly income could simply invest in a combination of bank certificates of deposits (COD) and high-grade corporate and… Read More